Nilforoushzadeh Mohammad Ali, Jaffary Fariba, Moradi Shahram, Derakhshan Roya, Haftbaradaran Elaheh
Skin Disease and Leishmaniasis Research Center (Sedigheh Tahereh), Isfahan University of Medical Sciences, Isfahan, Iran.
BMC Complement Altern Med. 2007 Apr 27;7:13. doi: 10.1186/1472-6882-7-13.
Leishmaniasis is an endemic disease in Iran. Although many treatments have been suggested for this disease, there hasn't been an effective and safe treatment yet. Regarding the healing effect of honey in the chronic ulcers and its reported therapeutic effect in cutaneous leishmaniasis, we performed a study to better evaluate the efficacy of honey in cutaneous leishmaniasis and its final scar.
In a prospective clinical trial, 100 patients with confirmed cutaneous leishmaniasis were selected and randomized into 2 groups. Group A were treated with topical honey twice daily along with intralesional injection of glucantime once weekly until complete healing of the ulcer or for maximum of 6 weeks. Group B were treated with intralesional injection of glucantime alone until complete healing of the ulcer or for a maximum of 6 weeks, too. The patients were followed for 4 months. The collected data were analyzed statistically using statistical tests including Chi-square, Mann Whitney and Kaplan-Mayer tests.
In this study, 45 patients that had cutaneous leishmaniasis were treated with intralesional glucantime alone and 45 patients were treated with topical honey and glucantime. Ten patients left out the study. In the glucantime alone treated group, 32 patients (71.1%) had complete cure whereas in the group treated with both glucantime & topical honey, 23 patients (51.1%) achieved complete cure. This difference was significant statistically (p = 0.04).
Further studies to better clarify the efficacy of honey in cutaneous leishmaniasis is needed. We suggest that in another study, the efficacy of honey with standardized level of antibacterial activity is evaluated against cutaneous leishmaniasis.
利什曼病是伊朗的一种地方病。尽管针对该疾病已提出多种治疗方法，但尚未有有效且安全的治疗方案。鉴于蜂蜜对慢性溃疡的愈合作用及其在皮肤利什曼病中所报道的治疗效果，我们开展了一项研究，以更好地评估蜂蜜在皮肤利什曼病及其最终瘢痕形成方面的疗效。
在一项前瞻性临床试验中，选取100例确诊为皮肤利什曼病的患者并随机分为两组。A组患者每天外用蜂蜜两次，同时每周进行一次病灶内注射葡糖胺聚糖，直至溃疡完全愈合或最长治疗6周。B组患者仅接受病灶内注射葡糖胺聚糖治疗，直至溃疡完全愈合或最长治疗6周。对患者进行4个月的随访。使用包括卡方检验、曼-惠特尼检验和卡普兰-迈耶检验在内的统计检验对收集的数据进行统计学分析。
在本研究中，45例皮肤利什曼病患者仅接受病灶内葡糖胺聚糖治疗，45例患者接受外用蜂蜜和葡糖胺聚糖治疗。10例患者退出研究。仅接受葡糖胺聚糖治疗的组中，32例患者（71.1%）完全治愈，而接受葡糖胺聚糖和外用蜂蜜联合治疗的组中，23例患者（51.1%）实现完全治愈。这一差异具有统计学意义（p = 0.04）。
需要进一步开展研究以更好地阐明蜂蜜在皮肤利什曼病中的疗效。我们建议在另一项研究中，评估具有标准化抗菌活性水平的蜂蜜对皮肤利什曼病的疗效。
